Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform

NEXT STORY
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
PREV STORY
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kura Oncology Announces Commencement of Public Offering of Common Stock

author_avatar
NASDAQ Market News

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

author_avatar
NASDAQ Market News

Montreal Chest Institute Foundation and MUHC Foundation join forces to change the course of lives and medicine

author_avatar
NASDAQ Market News